To date, the majority of work focusing on the LHb as a potential therapeutic target for MDD has aimed to reduce the excitability of LHb neurons (for reviews, see Nuno-Perez et al., 2018; Yang et al., 2018b; Hu et al., 2020). The gene discussed is LHB; the disease is major depressive disorder.